| Patent application number | Description | Published |
|---|
| 20080206230 | Peptides Derived from Human Bplp Protein, Polynucleotides Coding for Said Peptides and Antibodies Directed Against Said Peptides - The invention relates to a peptide that is a maturation product of the Basic Prolin-rich Lacrinal Protein (BPLP) or a peptide derivative of said maturation product, wherein the peptide or peptide derivative exhibits an inhibitory property against a metallo-ectopeptidase, especially NEP and/or APN. | 08-28-2008 |
| 20090253639 | OPIORPHIN PEPTIDE DERIVATIVES AS POTENT INHIBITORS OF ENKEPHALIN-DEGRADING ECTOPEPTIDASES - The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases. | 10-08-2009 |
| 20090298109 | METHOD FOR IDENTIFYING BPLP AND OPIORPHIN AGONISTS OR ANTAGONISTS - A method for in vitro functional characterization of Opiorphin derivatives by using highly selective biochemical assays. The method may employ an assay involving contacting an Opiorphin derivative with an enkephalin-inactivating ectopeptidase, such as neutral endopeptidase NEP (EC 3.4.24.11) or aminopeptidase AP-N (EC 3.4.11.2). This method provides a rapid and sensitive assay for measuring activity of these two membrane-anchored ectoenzymes when contacted with Opiorphin derivative by means of a selective fluorescence-based enzyme model. | 12-03-2009 |
| 20100041072 | PROCESS FOR IDENTIFYING A LIGAND THAT BINDS TO THE NEP BINDING SITE FOR THE SMR1 PENTAPEPTIDE - The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human. | 02-18-2010 |
| 20110124571 | OPIORPHIN PEPTIDE DERIVATIVES AS POTENT INHIBITORS OF ENKEPHALIN-DEGRADING ECTOPEPTIDASES - The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases. | 05-26-2011 |
| 20110178021 | OPIORPHIN FOR USE AS A PSYCHOSTIMULANT AGENT - The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and in children, depression, bipolar disease, dysthymic disorder and cyclothymic disorder. | 07-21-2011 |
| 20110244491 | PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES - The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject. | 10-06-2011 |
| 20120034604 | USE OF BASIC PROLIN-RICH LACRIMAL GENE PRODUCTS, SUCH AS OPIORPHIN, AS A BIOMARKER - The present invention relates to the use of Basic Prolin-rich Lacrimal protein (BPLP) gene products, such as Opiorphin, for establishing a prognosis, a diagnosis or the monitoring of a pathological state or of treatment efficacy in a subject and the related method of use. | 02-09-2012 |
